Other LHRH analogues have been shown to limit prostate carcinoma cell growth secondary to downregulation of EGFR (Moretti et al, 1996; Jungwirth et al, 1997a, 1997b) or through interference with signalling pathways initiated by the EGFR (Wells et al, 2002). This evidence concerns the gene EGFR and prostate carcinoma.